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Abstract
Endometriosis is a common benign gynaecological condition affecting at least 10% of women of childbearing age
and is characterized by pain – frequently debilitating. Although the exact prevalence is unknown, the economic
burden is substantial (∼$50 billion a year in the USA alone) and it is associated with considerable morbidity. The
development of endometriosis is inextricably linked to the process of menstruation and thus the models that best
recapitulate the human disease are in menstruating non-human primates. However, the use of these animals is
ethically challenging and very expensive. A variety of models in laboratory animals have been developed and the
most recent are based on generating menstrual-like endometrial tissue that can be transferred to a recipient animal.
These models are genetically manipulable and facilitate precise mechanistic studies. In addition, these models
can be used to study malignant transformation in epithelial ovarian carcinoma. Epidemiological and molecular
evidence indicates that endometriosis is the most plausible precursor of both clear cell and endometrioid ovarian
cancer (OCCA and OEA, respectively). While this progression is rare, understanding the underlying mechanisms of
transformation may offer new strategies for prevention and therapy. Our ability to pursue this is highly dependent
on improved animal models but the current transgenic models, which genetically modify the ovarian surface
epithelium and oviduct, are poor models of ectopic endometrial tissue. In this review we describe the various
models of endometriosis and discuss how they may be applicable to developing our mechanistic understanding of
OCCA and OEA.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Endometriosis is defined as the presence of endometrial
tissue (glands and stroma) outside the uterine cavity; it is
found primarily in the pelvis and can involve all organs
but particularly the ovaries and pelvic peritoneum. It is
a common condition affecting an unknown number of
women of reproductive age. Typical symptoms include
pain and subfertility, and the complexity and severity
of the pain can present major management challenges
[1,2]. Dysmenorrhoea affects up to 62% of women with
endometriosis, and is incapacitating in up to 28% [3].
Definitive diagnosis requires laparoscopy or laparo-
tomy and histological confirmation, but there is often a
protracted time to diagnosis (mean of 8.0 and 11.7 years
in the UK and USA, respectively) [4], due to the
complexity of the presenting symptoms. The annual
economic costs associated with delays in diagnosis are
substantial and were estimated at approximately $50
billion in the USA [5]. Management of pain symptoms
often combines analgesia, hormonal therapies such as
hormonal contraceptives, progestagens (either systemic
or more commonly local delivery of levonorgestrel
to the uterus), or gonadotropin-releasing hormone
(GnRH) analogues. Surgical treatments include abla-
tion or excision of endometriotic lesions or ovarian
cystectomy and occasionally hysterectomy and bilateral
salpingo-oophorectomy. The treatment of associated
subfertility is challenging and may be surgical or by
the use of assisted reproduction such as IVF. How-
ever, surgery carries risks of complications which may
themselves compromise fertility. Finally, adhesiolysis
and treatment of lesions carries a risk of injury to
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all pelvic structures [6]. These treatment modalities
vary in their effectiveness in relieving the pain and
increasing pregnancy rates, and also in their side-effect
profiles [7].
The concentration of a range of inflammatory medi-
ators – cytokines, growth factors, eicosanoids, and
angiogenic factors – is altered in the peritoneal fluid
of women with endometriosis [8–10]. Disturbance of
several of the immunomodulators has been implicated
in the endometriosis-associated infertility [11]. Here,
we review the relationship between endometriosis and
clear cell and endometrioid ovarian cancers and the
experimental models that may be used to investigate the
mechanisms underlying disease progression.
The origin of endometriosis
At present, there is no definitive answer for the origin
of endometriosis, but the most widely accepted theory
is that it arises from endometrium that has disseminated
to ectopic sites, most commonly by retrograde menstru-
ation [12–14]. Thus, menstrual tissue passes through
the fallopian tube and into the peritoneum, where it
attaches, invades, and grows into endometriotic lesions.
There is a genetic component to endometriosis risk and a
genome-wide association study has identified candidate
risk alleles [15].
Endometriosis has high prevalence, significant mor-
bidity, and considerable economic impact. The wide
range of treatments used in clinical practice under-
scores our limited understanding of the pathogenesis of
endometriosis and approaches that exploit new mod-
els and analytical techniques could have high utility.
Furthermore, although endometriosis itself is a benign
disease, several epidemiological studies have identified
it as a risk factor for some types of malignancies, most
notably ovarian cancer, and particularly ovarian clear
cell adenocarcinoma (OCCA) or ovarian endometrioid
adenocarcinoma (OEA). Models which allow the under-
lying mechanisms to be elucidated offer the prospect
of patient stratification and over the longer term,
new therapies.
Endometriosis and ovarian cancer
Epithelial ovarian cancers (EOCs) are not a single dis-
ease but rather a group of diseases with distinct mor-
phological and molecular features, all of which may
affect the ovary. The principal subtypes of EOCs are
high-grade serous carcinoma, low-grade serous carci-
noma, mucinous carcinoma, clear cell adenocarcinoma
(OCCA), and endometrioid adenocarcinoma (OEA).
These tumours likely have different cells of origin,
distinct histopathological features, and exhibit differ-
ent molecular profiles. However, all subtypes of EOCs
are treated by surgical debulking and platinum-based
chemotherapy. OCCA and OEA have high rates of pri-
mary resistance to platinum-based chemotherapy which
contributes to their poor prognosis when presenting with
late stage or reoccurrence.
Epidemiology
Endometriosis is now recognized as a likely precur-
sor of some subtypes of epithelial ovarian cancer. As
early as 1925, Sampson made the observation that can-
cer developed in ectopic endometrial tissue [16]. Since
then, multiple epidemiological studies have investigated
the association between endometriosis and ovarian can-
cer. Two large studies were carried out using the Swedish
Inpatient Register (NSIR) and National Swedish Can-
cer Registry. In the first [17], the authors studied all
patients discharged from hospital with a diagnosis of
endometriosis between 1969 and 1983 – a total of 20
686 patients. Among patients with well-documented
endometriosis, there was an increased risk of ovarian
cancer (SIR, defined as ‘the ratio of the observed num-
bers of cancer to those expected’, 1.9; 95% CI 1.3–2.8)
and the risk was particularly elevated in subjects with
a long-standing history of ovarian endometriosis (SIR
4.2; 95% CI 2.0–7.7). The second study also used the
NSIR to identify a large cohort of women diagnosed
with endometriosis between 1969 and 2000 [18]. When
25 430 women with ovarian endometriosis were anal-
ysed, the risk of ovarian cancer was increased, with an
SIR of 1.77 (95% CI 1.38–2.24), and this peaked 3–4
years after hospitalization to an SIR of 2.64 (95% CI
1.2–5).
A pooled analysis of 13 case–control studies (23
144 women) was used to examine the consistency and
degree of association between endometriosis and the
different subtypes of ovarian cancer [19]. Self-reported
endometriosis was consistently found to be associated
with an increased risk of invasive epithelial ovarian
cancer after taking into account confounding factors
(including study site, ethnic origin, oral contraceptive
pill use, and parity). Risk was strongly associated with
OCCA and OEA subtype (OCCA odds ratio 3.05, 95%
CI 2.43–3.84, p< 0 ⋅ 0001; OEA odds ratio 2.04, 95%
CI 1.67–2.48, p< 0.0001; and low-grade serous odds
ratio 2.11, 95%CI 1.39–3.20, p< 0.0001). However, the
history of endometriosis in these case–control studies
was self-reported and this may predispose to recall bias.
While it is presumed that cancer cases may be more
likely to report a history of endometriosis than controls,
it is likely that this bias is random and may not account
for the difference in association between the different
subtypes of ovarian cancer.
Molecular evidence for the relatedness
of endometriosis to OCCA and OEA
The consistent finding of increased risk in the above
epidemiological studies supports a two- to three-fold
increase in the risk of OCCA and/or OEA in patients
with endometriosis. However, it is plausible that a
common characteristic, such dysregulation of cytokine
production or steroid metabolism within the peritoneal
environment, predisposes to both conditions. How-
ever, there are several lines of molecular evidence
that suggest that OCCA and OEA arise directly from
endometriotic lesions. The first published studies used
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information from loss of heterozygosity (LOH) surveys
in OCCA and OEA cases to test whether identical
changes were also present in adjacent endometriosis.
In a study of 19 OEAs, 22 OCCAs, and 23 solitary
endometrial cysts, LOH at 10q23.3 (the gene locus of
PTEN) occurred in 42.1% (8 of 19) OEAs, 27.3% (6 of
22) OCCAs, and 56.5% (13 of 23) solitary endometrial
cysts. Importantly, in five OEAs and seven OCCAs
with synchronous endometriosis, three cases in each
group showed identical LOH events in both tumour and
endometriosis; one case in each group had LOH in the
tumour only. The remaining endometriosis cases (one
OEA and three OCCAs) did not show LOH events.
None of the endometriotic lesions showed LOH events
that were not also present in the co-existent tumours
[20]. These data suggest that loss of PTEN function by
LOH or mutation is an early event in the development
of endometriosis-related cancers of the ovary.
Similar findings were demonstrated using 82
microsatellite markers to detect LOH in ten OEA
and six OCCA cases with synchronous endometriosis.
A total of 63 LOH events were identified in the tumours,
with 22 found in the matched endometriosis tissue, and
in each case, the same allele was lost. LOH was not
noted in control endometriosis-only cases [21].
More recently, specific mutations and copy number
abnormalities have been demonstrated in tumour and
co-existent endometriosis. Wiegand et al sequenced the
entire exome of 18 OCCA samples and one OCCA cell
line, and the ARID1A gene in an additional 210 ovarian
cancers [22]. ARID1A was mutated in 46% of OCCAs
and 30% of OEAs, with 17 of the samples having two
somatic mutations each. No ARID1A mutations were
found in high-grade serous (HGS) specimens. Two of the
patients who had OCCA samples with ARID1A muta-
tions also had contiguous atypical endometriosis (ie with
epithelial cells showing nuclear enlargement, crowd-
ing, slight hyperchromasia, and possible chromocen-
tres/nucleoli and/or architectural abnormalities). One of
these patients had a truncating mutation and the other
had two somatic mutations predicting loss of BAF250a
protein (encoded by ARID1A). These mutations were
found in the contiguous atypical endometriosis but not in
distant endometriosis, further supporting local transfor-
mation of endometriosis tissue. Immunohistochemical
staining for BAF250a was also lost in both OCCA and
the contiguous atypical endometriosis but not in distant
endometriosis [22]. Taken together, these data strongly
support a model for early mutation of ARID1A during
malignant transformation of endometriosis.
These results were confirmed using immunohisto-
chemistry for BAF250a [23] in an independent series
of matched OCCA and endometriosis tissues. In that
study, the authors also sequenced exons 9 and 20 of
PIK3CA and found synchronous mutations in 17 of 42
(40%) of these tumours, most of which (71%) were
also ARID1A-deficient [23]. This suggests that PIK3CA
mutations also occur at a very early stage in the devel-
opment of OCCA, before the appearance of the atypical
precancerous lesions.
The MET proto-oncogene is frequently overex-
pressed in OCCA and is frequently amplified. Copy
number alterations and MET protein levels were stud-
ied in 13 tumours and precursor lesions [including
11 endometriosis and two clear cell adenofibromas
(CCAFs)]. MET copy number gain and overexpression
were demonstrated in the atypical precursor lesions.
Non-atypical endometriosis and benign CCAFs did not
demonstrate MET gain [24]. These data suggest that
MET gain is an early event in tumourigenesis in a subset
of OCCAs and that it is a driver mutation.
To further identify the pattern of somatic mutations
in OCCA and investigate whether there was a clonal
relationship between benign gynaecological lesions,
including endometriosis, and OCCA, whole-genome
sequencing of seven OCCAs was performed and tar-
geted sequencing of other co-existent adjacent or
metastatic tumours, endometriosis, and other benign
conditions [25]. Most of the mutations found in the
index tumour were also found in the other co-existent
cancer or borderline tumours in the same patient. There
were clusters of mutations present in both OCCA and at
least one focus of atypical or non-atypical endometriosis
from the same patient. No somatic mutations were found
in normal endometrium or non-endometriosis benign
lesions. Thus, atypical endometriosis shared nearly all
of the coding somatic mutations that were detectable in
the co-existent tumour and it is highly likely that these
mutations are ancestral events in the evolution of the
clear cell tumour. These findings support a model in
which different subtypes of endometriosis have differ-
ing malignant potential – however, the morphological
diagnosis of atypical endometriosis is difficult and these
data may also suggest a local field effect for mutational
change.
The studies described above, considered collectively,
make a compelling case for endometriosis being the pre-
cursor lesion of OCCA and OEA – although this pro-
gression is rare. The major clinical challenge is now to
determine which individuals are at higher risk of the
rare event of transformation of endometriosis to OCCA
or OEA. However, our understanding of the molecular
basis of this progression is far from complete. Effective
patient screening and therapeutic intervention will only
be possible once we have a fuller picture of the molecu-
lar pathways involved. Consequently, in the absence of
any effective screening for any ovarian cancer type, cur-
rent guidance is that no action be taken to monitor this
potential progression in women with endometriosis [6].
Such investigations are not possible in human subjects,
so it is necessary to use animal models. However, these
models need to be carefully selected and their limitations
recognized. The establishment, development, and rare
transformation of endometriosis take place in a complex
environment and the selectedmodel should replicate this
as closely as possible while allowing specific manipu-
lation and appropriate analysis. The importance of the
tissue microenvironment and the selective genetic mod-
ification at defined times has been well described in can-
cer models [26]. Such refined approaches should inform
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the design of studies of endometriosis. Here, we review
the animal models used in the study of endometriosis
and explore their suitability for improving our under-
standing of endometriosis and whether they represent
appropriate models to investigate the rare progression of
endometriosis to ovarian cancer.
Animal models of endometriosis
For any system to be a useful model of a human dis-
ease, it needs to recapitulate the typical features of that
condition but to be manipulable in a way that humans
are not. Thus, there may be a naturally occurring vet-
erinary condition that parallels the human disease; if so,
this could be used to investigate the molecular mech-
anisms underlying the disease. If this is not the case,
then a more interventional approach is needed. The
simplest and the most commonly accepted pathologi-
cal mechanism underlying endometriosis is the retro-
grade menstruation proposed by Sampson [27]. All the
models of endometriosis assume this mechanism and
rely on transferring endometrium to a site outside the
uterine cavity.
Spontaneous endometriosis in primates
Unlike other model organisms, some primates menstru-
ate and develop spontaneous endometriosis and this is
very similar to the human condition. For example, rhe-
sus monkeys (Macaca mulatta) develop endometriosis
that “anatomically and clinically, appears to be identical
to the human disease” [28]. The frequency in a captive
breeding colony was ∼1%, although in a more recent
study of animals aged≥ 10 years the prevalence was
∼31% [29]. In baboons (Papio anubis), the frequency
is broadly similar – 11% or 32% in animals held in cap-
tivity for less than 1 year or greater than 2 years, respec-
tively. This difference may be due to an increase in the
number of menstrual cycles (due to a reduction in the
number of pregnancies) [30].
Artificial induction of endometriosis in primates
Spontaneous endometriosis in primates can take sev-
eral years to develop. However, to study the onset and
progression of the disease, the variability and length
of time required for development of endometriosis are
a major limitation. This has been partially alleviated
by the development of methods that artificially induce
endometriosis in primates. In 1953, Scott et al diverted
the normal menstrual flow by repositioning the cervix
and clamping the descending uterine vessels [31]. The
ten rhesus monkeys used in this study were then mon-
itored a year later, after which five had viable endome-
trial stroma and glands, smooth and striated muscle, and
fibrous tissue in the area to which the diversion was
made. Similar results were obtained in baboons in which
the volume of retrograde menstrual flow was increased
by surgical occlusion of the cervix [32].
Induction of endometriosis by transplantation
Endometriosis is characterized by endometrial tis-
sue being ‘in the wrong place’. Hence, a reasonable
approach to making an experimental model is to collect
endometrium and transplant to an ectopic site.
Iatrogenic endometriosis as a complication of surgery
was seen to be so common that Ridley in 1968 wrote
“this fact is now growing so commonplace that it is
accepted and usually not reported in the literature” [33].
Thus, it is not surprising that the obvious approach of
autologous transplantation in primates was used to gen-
erate an animal model of endometriosis [34]. Surgically
excised fragments of endometrium were transplanted
into a number of sites in the peritoneum of rhesus
monkeys. Six of the seven monkeys had viable grafts
up to 522 days after transplantation. Other studies have
used minced or enzymatically digested endometrium
in cynomolgus monkeys (Macaca fascicularis). After
3 weeks, 76% of the subjects had endometriosis [35].
When endometrial fragments were collected during the
menstrual phase and introduced into the peritoneum of
baboons by injection, endometriosis developed in a very
similar manner to the spontaneous disease [36]. This
model showed that endometriosis could be caused by
material introduced using less invasive methods and was
thereby similar to humans in that the fragments seed
wherever they land. However, as the material was col-
lected by curettage, it contained tissue from layers of the
endometrium that would not be found inmenstrualmate-
rial. A similar model, but using a pipelle (endometrial
suction curette) to collect tissue at the time of menstru-
ation, was used in the identification of ERα, MMP-7,
VEGF, and aromatase in endometriotic lesions [37,38].
The effects of the presence of endometriosis on the
eutopic endometrium have been studied in humans [39],
and similar questions have been addressed using the
baboon model. Endometriosis was induced and uterine
endometrium sampled in the mid-secretory phase 1, 3,
6–7, 10–12, and 15–16 months after endometriosis
induction. Transcript profiling was carried out and
showed that during the early stages of the disease,
there was an oestrogenic dominant phenotype in the
eutopic endometrium. As the condition progressed,
the endometrium became progesterone-resistant. In
addition, several signalling pathways, including the
ERK/MAPK and PI3/AKT, were dysregulated and
expression of genes such as KRAS, FOS, and NODAL
was altered [40]. Using the same approach to induce
endometriosis led to increased Cyr61 (an angiogenic
protein) in the eutopic endometrium [41].
In many ways, primate studies are attractive because
these animals are closely related to humans, anatom-
ically and physiologically, and spontaneously develop
the disease, suggesting that the peritoneal environ-
ment is similar. These studies exemplify the useful-
ness of the baboon as a model animal for the study
of endometriosis – the endocrine environment is simi-
lar to that in humans and can be well controlled; the
induction of endometriosis is uniform and under tight
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temporal control; it is possible to visualize the lesions
and collect samples over a prolonged time; and, lastly,
the animal cycles naturally. This is counterbalanced by
more complex handling and housing requirements; thus,
experimental work with primates is costly and ethically
challenging.
Rodent and rabbit models
Laboratory animals do not menstruate and never develop
spontaneous endometriosis. However, hamsters, rabbits,
and particularly rats and mice are widely used as sci-
entific models for medical research, due to their short
generation times and their ease of physiological and
of particularly genetic manipulation. Rabbit and rodent
models of endometriosis have been established based on
transplanting endometrium or uterine fragments, either
from the same species (homologous models) or from
humans (heterologous models), to ectopic sites.
A rabbit model of endometriosis was generated to
study the effects of endometriosis on fertility [42].
Endometrium was transplanted from one horn of
the uterus into the peritoneum. The concentration of
prostaglandin in the peritoneal fluid increased and the
pregnancy rate dropped 25%. Transplanted material
was still present 12 weeks later, and had become cystic
and similar to the lesions seen in humans [43]. Such
studies suggested that the presence of endometrium in
the peritoneum caused changes in the local environ-
ment, which could explain the reduced fertility. This
rabbit model was useful for identifying changes in the
peritoneal environment and has the advantage that the
ectopic tissue grows without supplementary oestrogen
and the host ovaries and immune system are intact.
Homologous rodent models
Both rat and mouse models have been generated by
autotransplantation of fragments of the uterus to the
mesentery [44,45]. This tissue developed into fluid-filled
cysts which grew for approximately 2 months, before
remaining stable for at least 10 months (in rats). In
both species, epithelial and stromal cells were present.
However, in this model, both the endometrium and the
myometrium were transplanted, and so the resulting
cysts were made up of both endometrial and myometrial
tissue. Given that endometriosis by its very nature is
endometrium-derived, this model does not represent an
ideal model of the disease. When the endometrium was
scraped from the myometrium and ‘flushed’ into the
peritoneal cavity, no lesions developed [44].
A model in which only the endometrium is trans-
planted has been developed. The endometrium was
collected from ovariectomized and oestrogen-treated
mice. It was minced and injected into the peritoneum
of syngeneic recipient animals [46]. The recipients
were also treated with exogenous oestradiol and the
resulting lesions were allowed to develop for ∼3weeks.
Endometriosis is an oestrogen-dependent disease;
indeed, as already described, many of the therapeu-
tic strategies rely on reducing circulating oestradiol
or opposing its action. This model uses high doses
of oestradiol to stimulate endometrial growth before
collection and then similar doses to stimulate lesion
growth in the recipient animals. The authors recognize
that this may be one of the reasons why they were able
to generate lesions when previous attempts without
oestrogen stimulation failed. This strong oestrogen
drive may limit the usefulness of this model and women
with endometriosis do not have elevated oestradiol
levels.
An enhancement of this model which improved the
quantitative assessment of lesion growth made use of
donor mice in which green fluorescent protein (GFP)
was ubiquitously expressed [47]. As the donor cells are
all genetically tagged and can be readily detected by
fluorescent microscopy, the location and the intermixing
of donor and recipient cells can be observed. These
authors also demonstrated that the lesions grew poorly
in the absence of exogenous oestradiol [47].
While it is possible to image GFP in the inter-
nal organs of a mouse [48] (and hence endometriotic
lesions), the sensitivity is relatively low. Bioluminescent
imaging using luciferase-expressing cells has greater
sensitivity and allows non-invasive monitoring of lesion
development. Transgenic mice with the human ubiqui-
tin C promoter coupled to firefly luciferase have been
used as the donors in the endometriosis model described
above [45,49]. The uterus of a UbC-Luc+/+ mouse was
collected and the horns were opened to allow numer-
ous 2-mm tissue samples to be punched out. Four of
these were then sutured into separate peritoneal loca-
tions in albino recipient mice. The luciferase-derived
signal level was measured 2 weeks post-surgery and
showed a clear signal in the location of suture sites. The
micewere culled 2weeks later and the lesions examined.
All showed similarity to human endometriosis lesions,
with evidence of angiogenesis. This approach is a sig-
nificant advance as lesion growth can be serially moni-
tored non-invasively for up to 35 days [49]. The origin of
infiltrating cells can be tracked in thismodel using genet-
ically tagged donor (with GFP, for example) or recipi-
ent animals. This model is well suited to monitor lesion
response to drugs that inhibit new vessel formation [50].
Nonetheless, it has the limitations of the transplantation
models described above, due to the presence of both the
endometrium and the myometrium.
Spontaneous mouse endometriosis
In 2005, the first mouse model in which endometriosis
developed without any form of transplant was described
[51]. Activating K-ras in loxP-Stop-loxP-K-rasG12D/+
mice (LSL-K-rasG12D/+) by injecting Cre-adenovirus
into the ovarian bursa resulted in the development
of endometriotic-like lesions (endometrial glands but
no stroma) in the ovarian surface epithelium in all
the mice, and endometriotic lesions with both glands
and stroma in the peritoneum in 47% of the animals.
When similarly transduced ovaries were transplanted,
the endometriotic-like lesions were limited to the
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ovarian surface epithelium. This suggests that the
endometriotic-like lesions on the ovary in this mouse
model most likely arose from the ovarian surface
epithelium itself. However, the peritoneal lesions
probably arose from uterotubal cells in which K-ras
was activated along the needle track. Injection of
AdCre virus directly into the peritoneal cavity of the
LSL-K-rasG12D/+ mice did not lead to the development
of any endometriotic-like lesions, suggesting (in mice
at least) that endometriosis does not arise through meta-
plastic transformation of the peritoneum [51]. These
authors exploited their novel methodology and intro-
duced additional mutations. Injection of AdCre virus
into the ovarian bursa of LSL-K-rasG12D/+;PtenloxP/loxP
mice leads to signs of invasive ovarian endometrioid
adenocarcinoma between 7 and 12 weeks later. How-
ever, the unintended transduction of tubular cells (which
was clearly demonstrated in this study) may in fact be
an important characteristic of this method of delivering
the Cre. While the method provides clear information
about the function of the genes manipulated, conclu-
sions about the precise cell of origin need to be drawn
cautiously. Nonetheless, the presence of the K-ras
mutation in this model overcame the need for additional
hormone stimulation and provides a useful model to
study the histomorphology and biological behaviour of
endometriosis.
‘Menstrual’ rodent models
Endometriosis is a condition in which normal menstrual
material persists in an abnormal environment. Thus, an
animal model of this condition would ideally mimic the
processes that allow this material to adhere within the
peritoneum and develop into a lesion. Indeed, this was
the basis of the initial models in primates. Clearly, rodent
models havemany attractions but they do not menstruate
naturally.
A mouse model has been developed to mimic the
endometrial breakdown seen in human menstruation. In
this model, ovariectomized mice are treated with oestra-
diol and progesterone and the endometrium is stimulated
to decidualize by injecting a small amount of oil directly
into the uterine lumen. Examination 48 h after cessa-
tion of the hormone injections (ie progesterone with-
drawal, as occurs at the end of the menstrual cycle)
revealed blood vessels filled with swollen erythrocytes,
apoptotic changes, and invasion of leukocytes. By 79 h
post-withdrawal, blood cells and degenerating decidual
cells had been shed into the uterine lumen [52]. This
model is suitable for exploring the processes that take
place in humans following luteal regression; however,
one of the limitations of this model is the variation in
the endometrial response.
This model has been refined: C56J/Bl6 ovariec-
tomized mice were exposed to a programme of
oestrogen injections to mimic the levels seen in the
human cycle. However, progesterone was delivered via
an implant inserted prior to the injection of oil into
the uterus. The removal of the implant 49 h after the
decidualizing stimulus allowed a more dramatic drop
in serum progesterone levels, more closely represent-
ing the human cycle. Mice were sacrificed and the
uterine response was examined 16, 24, 36, and 48 h
post-progesterone withdrawal. After 16 h, breakdown
of the endometrium was observed; by 24 h, the decidual
zone had separated from the rest of the endometrium.
Tissue debris was fully cleared by 36 h after proges-
terone withdrawal and by 48 h, the endometrium was
restored to its pre-decidual state [53]. A similar study
with additional molecular analysis has also been carried
out [54].
These two studies form the basis of related but dis-
tinct models of endometriosis [55,56]. In both cases,
mouse endometrium is decidualized by hormone pre-
treatment and an interuterine injection of oil. Proges-
terone treatment is withdrawn and 2.5–4 days later,
‘menstrual’ endometrium is collected and transferred to
a recipient animal. The two models differ in the dura-
tion and strength of the progesterone-stimulated decid-
ual growth: Cheng et al do not give progesterone after
the injection of the oil into the uterine lumen [55]. In
contrast, Greaves et al leave a progesterone implant in
place for 4 days after the interuterine oil injection [56].
The work of Dinulescu et al (described above)
showed that activation of K-ras was sufficient to gen-
erate an endometriosis-like lesion in the peritoneum of
mice [51]. These authors suggested the possibility of
“the peritoneal endometriosis having a uterine or tubal
origin” in the LSL-K-rasG12D/+ mice. Thus, a small
number of cells in which the LSL-K-rasG12D/+ had been
activated were sufficient to lead to endometriosis.
Cheng et al used a LSL-K-rasG12V/+/Ah-Cre+/+/
ROSA26R-LacZ +/+ mouse in which Cre was induced
in the uterus by β-naphthoflavone dissolved in the oil
used as the decidualizing stimulus [55]. The Cre then
locally activated the mutated (active) K-ras and the
LacZ reporter. After progesterone withdrawal, this
endometrium was transferred to a subcutaneous pocket
in wild-type intact animals. No exogenous steroids were
administered to the recipient animals but lesion growth
could be inhibited by treatment with an oestrogen
receptor antagonist (fulvestrant, ICI182780). In the
absence of the genetic modification, the ‘menstrual’
endometrium did not form lesions. Somewhat sur-
prisingly, only a small proportion of the cells in the
endometriotic lesions were LacZ-positive, suggesting
that Cre-mediated recombination did not occur in all the
endometrial cells, but that this low level of K-ras activa-
tion was sufficient for lesion establishment [55]. These
authors did not describe the fate of the engineered men-
strual tissue if it was injected into the peritoneal cavity.
Nonetheless, lesion growth was robust and accompa-
nied by the growth of surrounding blood vessels that
supplied the lesion, as illustrated in Figure 1A.
The extended progesterone treatment during decidual-
ization used by Greaves et al is more efficient and yields
a greater mass of ‘menstrual’ material for transplant.
However, a significant difference in this model is that the
recipient animal is primed with and continues to receive
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Figure 1. Examples of lesions generated using the models described
as ‘menstrual’ rodent models and heterologous rodent mod-
els in the main text. (A) Subcutaneous endometriotic lesion
in a C57Bl/6 Tyr−/− mouse following transplantation from
LSL-K-rasG12V/+/Ah-Cre+/+/ROSA26R-LacZ+/+ mice following the
method of Cheng et al [55]. (B) Subcutaneous endometriotic lesion
in a xenograft model in a Balb/c nu/nu mouse. Scale bar= 2mm.
The work to produce this figure was carried out in accordance with
the UK Home Office Animals (Scientific Procedures) Act 1986.
oestradiol; thus there is a strong oestrogenic drive which
promotes endometriotic lesion growth [56]. Despite this
limitation, this model has the advantage that it is simpler
than that of Cheng et al as there is no need for com-
plex animal breeding. This is a considerable advantage
as it facilitates the inclusion of other genes of inter-
est (reporter or functional). Indeed, this approach has
been effectively used to show that both host- and shed
tissue-derived macrophages are present in the growing
lesions [56].
Heterologous rodent models
An alternative to auto- or syngeneic-transplant is to
use human endometrium and immunodeficient mice
as recipients. Collectively, these have the advantage
that human tissue is used, so drugs or antibodies with
species-specific effects can be used. However, they have
the disadvantage that the host immune system is severely
compromised. Given that endometriosis is recognized as
an inflammatory condition, this is a significant weakness
in these models [1].
Multiple studies have described the transplantation
of proliferative, secretory, and menstrual phase human
endometrium into athymic nude mice [57–62]. Tissue
has been placed in or injected into the peritoneal cavity
[59,60,62], or transplanted subcutaneously [58]. In some
of the studies, the mice were ovariectomized and treated
(or not) with oestradiol [57], and in others, the ovaries
remained intact [60]. Given what is known about human
endometriosis, it is not surprising that in animals treated
with exogenous oestradiol, the lesions had a higher
proportion of proliferating cells [61].
Studies using this model have shown that angiogene-
sis is required for lesion growth, murine endothelial cells
grow into the lesion, and that it is VEGF-A derived from
the human tissue that drives this [60,63]; indeed, numer-
ous blood vessels can been seen around the developing
lesion shown in Figure 1B. Another useful characteris-
tic of this model is that host and donor cells can be
distinguished. An additional advantage to that obtained
by using fluorescently labelled donor cells (as described
earlier [47]) is that specific transcripts derived from the
host or donor can also be identified [64].
These studies broadly agree on the importance
of oestradiol, angiogenesis, and invasion for lesion
growth. However, the models are not well suited
to investigating the underlying mechanisms. For
example, there is considerable heterogeneity in the
tissue source – human endometrium or endometriotic
lesions [65], and a variety of additional different immun-
odeficient mouse strains have been used (NOD-SCID
[61] and RAG-2/γ(c)KO [65]). Uniform genetic modifi-
cation of the human tissue fragments is challenging and
while the mice can be modified by breeding in the alle-
les of interest, immunodeficient mice tend not to breed
very well. In an interesting approach to tackle some of
these limitations, Masuda et al prepared a single-cell
suspension of the glandular and stromal portions of
human endometrium and transplanted this under the
kidney capsule of ovariectomized NOD/SCID/γcnull
mice. The mice were treated with oestrogen pellets
with or without cyclic injections of progesterone. All
mice transplanted were found to have endometrium-like
tissue in the kidneys when collected 10 weeks later,
compared with only one of the 12 non-hormone-treated
mice. Mice that received oestrogen and progesterone
produced larger cysts than those treated with oestrogen
alone. Introduction of a YFP or luciferase gene into
the human cells prior to transplantation allowed lesion
growth to be followed for 8 weeks using non-invasive
imaging. A cyclic increase and decrease in signal could
be detected in the mice when progesterone was given or
withdrawn, showing that the cyclic events of the men-
strual cycle could be recapitulated in this model [66].
Such a model would also be useful in testing potential
treatments of endometriosis. However, this model is
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Table 1. Summary of the main characteristics of the animal models of endometriosis
Model [ref] Tissue transplanted
Menstrual
tissue used Immunocompetent
Exogenous oestrogen
required
Genetic modification
needed
Genetically
manipulable
Baboon [36] Endometrium Yes Yes No No No*
Rabbit [42] Endometrium No Yes No No No*
Rat [44] Myometrium and endometrium No Yes Yes No Yes
Mouse [45] Myometrium and endometrium No Yes Yes No Yes
Mouse [46] Endometrium No Yes Yes No Yes
Mouse [51] NA No Yes No Yes Yes
Mouse [55] Endometrium Yes Yes No Yes Yes
Mouse [56] Endometrium Yes Yes Yes No Yes
Mouse [57] Human endometrium Yes/no† No Yes/no‡ Yes Yes§
*The donor is not currently genetically manipulable and although in principle ex vivo viral transduction would be possible, this has not been demonstrated.
†Human endometrium from any phase of the cycle forms lesions in this model.
‡Exogenous oestradiol is frequently used but is not absolutely required.
§The donor is not genetically manipulable, although in principle ex vivo viral transduction is possible and this has been presented in abstract form (O144) [74].
limited as the recipient is immunocompromised and the
site of transplantation is not typical of endometriosis,
and so does not aid our understanding of adhesion to
the peritoneal surface or the seeding of the ovary.
Overview of endometriosis models
As summarized above, recent animal models of
endometriosis have become more refined and now
are able to recapitulate the presumed pathogenesis of
the human condition. As might be expected, primate
models are the closest to human disease but are ethi-
cally difficult and very expensive. Rodent models, which
mimic the deposition of menstrual tissue, are now avail-
able and have the advantage of being easily genetically
manipulable and immunocompetent. However, the need
for exogenous oestradiol in rodents may be a limita-
tion – for example, if studying a process that is directly
oestrogen-dependent. However, the complex breeding
required to use the model described by Cheng et al is a
significant disadvantage [55]. The principal features of
the available models are summarized in Table 1.
Mouse models of epithelial ovarian cancer
It is now understood that ovarian cancer is a heteroge-
neous disease originating from different epithelial cells
in the Müllerian tract, which show marked tropism for
spread and growth on the ovary. As early as 1925, Samp-
son recognized this and said of ovarian endometriotic
lesions: “The ovarian implants are usually more active
than the latter (peritoneal), thus suggesting that ovarian
tissue is the most fertile soil” [16]. Thus, any ovarian
cancer model used to study the development of the dis-
ease should take into account the tissue or cell of origin
and the environmental cues that may determine growth
at ectopic sites. Recent elegant studies have begun to
shed light on the mechanisms which may explain why
the ovary is the favoured site for tumour deposition
and invasion [67]. Labelled ovarian cancer-initiating
cells (OTICs) were injected into the uterine horns of
superovulated mice. As early as 5 days later, fluores-
cent signal could be detected around the ovary by in
vivo imaging. Histological examination showed labelled
cells close to site of the corpus luteum and disrupted
epithelium. After 10 days, the cancer cells had invaded
the ovarian stroma, leaving an intact ovarian epithe-
lium. While this experiment used OTICs derived from
high-grade serous carcinoma, it demonstrates that these
cells are attracted to the ovary. This is likely to be the
case for the other types of epithelial ovarian cancers
whose cells of origin are different but which lodge in
the ‘fertile soil’ of the ovary.
The work of Dinulescu et al described above was a
significant advance in the development of mouse mod-
els of ovarian disease because of the innovative tar-
geting of genetic modifications to a specific site [51].
The method has been used to modify other genes impli-
cated in ovarian cancer. For example, Arid1a loss and
Pik3ca activation after intrabursal injection of AdCre in
Arid1afl/fl(GT)Rosa26Pik3ca*H1047R mice leads to rapid
development of ovarian cancer with OCCA-like histol-
ogy [68]. Approximately half of the mice had peritoneal
metastasis, often in the contralateral control (uninjected)
ovary, again pointing to the propensity of tumour cells
to seed in the ovary [67]. This study replicates the two
molecular defects that are known to co-exist in human
OCCA and thus can be used to study preventative or
therapeutic options. However, a weakness of this study
is the fact that OCCA is induced from OSE – or possi-
bly uterotubual cells as found by Dinulescu et al [51].
If the tumour in fact arose in the OSE, then the model
is not applicable to the study of the role of other Mül-
lerian epithelia or other possible precursors, such as
endometriosis in the development of OCCA. Similarly,
the ablation of Arid1a and Pten (a phosphatase that
inhibits the Pik3ca signalling cascade) using intrabursal
AdCre in Arid1afl/fl;Ptenfl/fl animals led to the develop-
ment of endometrioid ovarian tumours [69].
The Wnt/β-catenin pathway has been implicated in
OEA by mutational profiling studies and functionally
tested using models similar to those outlined above [70].
ApcloxP/loxPPtenloxP/loxP mice only develop tumours (with
the histological features characteristic of OEA) after
intrabursal AdCre. The relationship of these pathways
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Table 2. Summary of the main characteristics of the animal models of clear cell and endometrioid ovarian cancer
Model [ref] Immunocompetent
Genetic
modification needed
Genetically
manipulable
Genes
manipulated Site of origin of tumour in mouse model
Mouse OEA model [51] Yes Yes Yes Kras, Pten OEA probably from endometriosis-like lesions
on ovarian surface epithelium (glands but
no stroma)
Mouse OCCA model [68] Yes Yes Yes Arid1a, Pik3ca OCCA arose from ovarian surface epithelium
Mouse OEA model [69] Yes Yes Yes Arid1a, Pten OEA arose from ovarian surface epithelium
Mouse OEA model [70] Yes No Yes Apc, Pten OEA arose from ovarian surface epithelium
Mouse OEA model [71] Yes No Yes Apc, Pten, Trp53 OEA arose from ovarian surface epithelium
Figure 2. Schematic diagram showing features of endometriosis and postulated mechanisms contributing to the progression of clear
cell ovarian cancer. The peritoneal environment in patients with endometriosis is characterized by inflammation [56,75,76]. Exome
sequencing detected somatic mutations in paired eutopic and ectopic endometrium, with a higher burden in ectopic tissue. However, “these
mutations occurred in a mutually exclusive manner” [77]. Endometriotic lesions and particularly those adjacent to the OCCA carry multiple
tumour-associated somatic mutations [25]. The ovary and particularly the ovulation sites are favoured seeding sites for endometriosis and
probably tumour cells [67].
to other pathways implicated in ovarian cancer can ele-
gantly be studied using enhancements of this model: for
example, the role of Tp53 (which is infrequentlymutated
in OCAA but nearly ubiquitous in HGS) [71].
These mouse models replicate many but not all of
the features of human OEAs or OCCA, but can now be
extended to study in more detail the genetic alterations
required for tumour development and progression. This
will improve the use of these models to develop new
therapies and to study treatment response. However,
other models are needed to study the progression of
endometriosis into OEA. If in the model the cancer
arises in the OSE (the predominant target of intrabursal
delivered AdCre), then this is probably the wrong cell
type. On the other hand, as the mode of delivery of the
Cre (intrabursal injection) also targets a modest number
of uterotubal cells, the possibility remains that these
cells make a contribution to the pathology observed. The
principal features of these models are summarised in
Table 2.
Conclusions
When designing and using animal models of human
disease, and specifically endometriosis, it is important
to replicate the disease as closely as possible by tak-
ing into account the presumed tissue or cell of ori-
gin. The models of endometriosis all presume that the
underlying mechanism depends on dissemination of
endometrium by retrograde menstruation [27], and such
models have been developed in non-human primates and
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Figure 3. Schematic diagram of how the recently developed models
of endometriosis in mice can be applied to the study of progression
to clear cell carcinoma.
more recently in mice. These allow precise cellular and
molecular studies of the pathogenesis of endometriosis
but challenges remain. In particular, pain is a critical
symptom of endometriosis and the ideal model should
enable investigation of the complex interaction between
the endometriotic tissue, the inflammatory peritoneal
environment, locally growing nerve fibres, and the cen-
tral nervous system. Some of these interactions are now
being investigated [72,73].
The epidemiological and the molecular data reviewed
above very strongly suggest that the genesis of OCCA
and OEA is not in the ovary – although the ovary is
clearly a favoured seeding site. Thus, when developing
improved models to study cancer progression, new
approaches for targeting endometriosis cells in an
appropriate environmental context are now required.
The current models very elegantly demonstrate the inter-
play between genes and do cast light on the processes
important for uncontrolled growth in the peritoneal
environment. However, they do not fully address the
nature of the presumed progression in humans. The
nature of somatic changes necessary for the progression
from eutopic endometrium to endometriosis, and then
(rarely) to ovarian clear cell or endometrioid carcinoma,
remains to be defined. As indicated in Figure 2, the
peritoneal environment is likely to be a key determinant
in this process.
Over the last 5 years, animal models of endometrio-
sis and those developed to study epithelial ovarian
cancer have improved significantly. There is now
the prospect of combining genetic modification of
murine endometrium with the ‘menstrual mouse’ mod-
els of endometriosis to define the role of single or
combinations of particular genes in endometriosis and
OCCA or OEA. Potential risk alleles identified from
human genetic studies can be functionally tested in a
model of the presumed precursor lesion. An outline of
this approach is shown in Figure 3. Such advances in
both fields could lead to new diagnostic and therapeutic
strategies and this opportunity should be exploited for
the benefit of women.
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